Yasemin ÖZLÜK, Dilek YILMAZBAYHAN, Murat KARA, Berk ÇİMENOĞLU, Berker ÖZKAN, Eren ERDOĞDU, Salih DUMAN, Fahmin AMIROV, Alper TOKER

Prognostic factors in patients undergoing pulmonary resection for sarcomatoid carcinomas of the lung

Background: Pulmonary sarcomatoid carcinomas are very rare lungneoplasms, and no consensus exists regarding their optimal treatment.The prognosis of sarcomatoid carcinomas has been reported to be unfavorable compared with non-small-cell lung cancers; however, prognostic factors in patients undergoing surgery for sarcomatoid carcinomasremain unclear.Aims: To analyze clinicopathologic prognostic factors and survivaloutcomes in patients who underwent surgery for pulmonary sarcomatoid carcinoma.Study Design: Retrospective cross-sectional study.Methods: We designed a retrospective cross-sectional study in patientswho underwent surgery for pulmonary sarcomatoid carcinomas andstatistically analyzed the prognostic factors regarding clinicopathologicfeatures with respect to survival outcomes.Results: We had a total of 44 patients with sarcomatoid carcinoma whohad pulmonary resection. Sex distribution was 34 (77%) males and 10(22.7%) females, which was determined by declaration. The mean ageof patients was 57.3 ± 16 years with a median of 60 years. The 5-yearprogression-free survival and overall survival rates were 59% and 58%,respectively. The 5-year survival rates were significantly different fortumors > 5 cm (P = 0.044), tumorstatus (T) (P=0.016), lymph node status (N) (P=0.005), and pathologic tumor-node-metastasis (TNM) stage(P = 0.0001 ). However, histologic subtype (P = 0.628) and adjuvanttreatment (P = 0.804) did not have any significant effect on survival.Similarly, the significant prognostic factors in univariate analysis weretumor size (P = 0.085), T status (P = 0.005), N status (P = 0.028), andpathologic TNM stage (P = 0.0001). Multivariate analysis showed onlyT status (P = 0.058), N status (P = 0.018), and pathologic TNM stage(P = 0.019) as independent prognostic factors, with statistical power of87%, 43.1% and 21.2%.Conclusion: Surgery appears to be an optimal treatment with favorableoutcomes for patients with pulmonary sarcomatoid carcinoma. Patientswith small tumors at earlier stages are very likely to benefit from surgery, regardless of histologic subtype.

PDF

___

1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th edn. IARC 2015; 88-94.
2. Roesel C, Terjung S, Weinrich G, et al. Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages. Interact Cardiovasc Thorac Surg. 2017;24(3):407-413. [Crossref]
3. Rahouma M, Kamel M, Narula N, et al. Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results database. Eur J Cardiothorac Surg. 2018;53:828-834. [Crossref]
4. Park JS, Lee Y, Han J, et al. Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung. Oncology. 2011;81(3-4):206-213. [Crossref]
5. Huang SY, Shen SJ, Li XY. Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases. World J Surg Oncol. 2013;11:252. [Crossref]
6. Ung M, Rouguette I, Filleron T, et al. Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung. Clin Lung Cancer. 2016;17(5):391-397. [Crossref]
7. Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol. 2013;8(12):1574-1577. [Crossref]
8. Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. Surgery. 2012;152(3):397-402. [Crossref]
9. Bae H-M, Min HS, Lee SH, et al. Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer. 2007;58(1):112-115. [Crossref]
10. Corrin B, Chang YL, Rossi G, et al. Sarcomatoid carcinoma. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart (World Health Classification of Tumours). Lyon: IARC Press: 2004. P. 53-8.
11. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005;40(2):90-97. [Crossref]
12. Travis WD. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med. 2010;134(11):1645-1658. [Crossref]
13. Kaira K, Endo M, Abe M, et al. Biologic correlates of ¹8 F-FDG uptake on PET in pulmonary pleomorphic carcinoma. Lung Cancer. 2011;71(2):144-150. [Crossref]
14. Martin LW, Correa AM, Ordonez NG, et al. Sarcomatous carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg. 2007;84(3):973-980. [Crossref]
15. Maneeil K, Xue Z, Liu M, et al. Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients. Clin Lung Cancer. 2018;19(3):e323-e333. [Crossref]
16. Koss MN, Hochholzer L, Frommelt RA. Carcinosarcomas of the lung: a clinicopathological study of 66 patients. Am J Surg Pathol. 1999;23(12):1514-1526. [Crossref]
17. Pelosi G, Fraggetta F, Nappi O, et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol. 2003;27(9):1203-1215. [Crossref]
18. Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer. 2009;125(10):2479-2482. [Crossref]
19. Leone A, Graziano P, Gasbarra R, et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer. 2011;128:732-735. [Crossref]
20. Stiles BM, Nasar A, Hussein MK, et al. Routine molecular testing of resected early-stage lung adenocarcinoma with targeted next-generation sequencing demonstrates a high rate of actionable mutations. J Thorac Oncol. 2016;11(2):44-45. [Crossref]
21. Cimpeanu E, Ahmed J, Zafar W, et al. Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: a case report. World J Clin Cases. 2020;8(1):97-102. [Crossref]
22. Matsumoto Y, Miura T, Horiuchi H, Usui K. The Successful treatment of pulmonary pleomorphic carcinoma with pembrolizumab: a case report. Case Rep Oncol. 2017;10(2):752-757. [Crossref]